Biosig Technologies (NASDAQ:STEX) CIO Mitchell Young Williams Sells 23,810 Shares

Biosig Technologies, Inc. (NASDAQ:STEX) CIO Mitchell Young Williams sold 23,810 shares of Biosig Technologies stock in a transaction on Monday, June 1st. The stock was sold at an average price of $1.05, for a total value of $25,000.50. Following the transaction, the executive owned 3,013,838 shares in the company, valued at approximately $3,164,529.90. This represents a 0.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mitchell Young Williams also recently made the following trade(s):

• On Friday, May 1st, Mitchell Young Williams sold 263,863 shares of Biosig Technologies stock. The stock was sold at an average price of $0.79, for a total value of $208,451.77.

Biosig Technologies Stock Down 13.5%

Shares of NASDAQ:STEX opened at $1.19 on Wednesday. The business’s 50-day simple moving average is $1.12. The firm has a market cap of $215.43 million, a P/E ratio of -0.12 and a beta of 1.85. Biosig Technologies, Inc. has a 12-month low of $0.70 and a 12-month high of $14.11.

Biosig Technologies (NASDAQ:STEX) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

STEX has been the subject of several research reports. Wall Street Zen downgraded Biosig Technologies from a “hold” rating to a “strong sell” rating in a research report on Sunday, April 5th. Needham & Company LLC decreased their target price on Biosig Technologies from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, May 21st. Finally, Weiss Ratings upgraded Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.00.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.